SARS-CoV-2 Receptor Binding Domain (RBD) Protein–Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques
Authors:
- Puthupparampil V. ScariaPSPuthupparampil V. Scaria
- Christopher G. RoweCRChristopher G. Rowe
- Ivan KosikIKIvan Kosik
- Zhe HuZHZhe Hu
- Jonathan P. RennJRJonathan P. Renn
- Nada AlaniNANada Alani
- Pinar KemanliPKPinar Kemanli
- Sachy Orr-GonzalezSOSachy Orr-Gonzalez
- Lynn E. LambertLLLynn E. Lambert
- Kayode AdeyemiKAKayode Adeyemi
- Justin Y. A. DoritchamouJDJustin Y. A. Doritchamou
- Emma K. BarnafoEBEmma K. Barnafo
Open Access
Abstract
Background/Objectives: Rapid development of vaccines against SARS-CoV-2 was pivotal to controlling the COVID-19 pandemic. The emergency also provided a rare opportunity to test novel vaccine platforms such as mRNA in large clinical trials. Most of the early vaccines used SARS-CoV-2 Spike protein as the target antigen. Nevertheless, subsequent studies have shown that Receptor Binding Domain (RBD) of Spike also can yield efficacious vaccines, and we previously demonstrated that chemical conjugation of RBD to a carrier protein, EcoCRM®, enhanced antibody responses and induced strong virus neutralization activity in mice. Methods: Here, we compared the immunogenicity of this conjugate to that of an approved mRNA vaccine from Pfizer/BioNTech in rhesus macaques over a period of nine months. Results: AS01-adjuvanted RBD conjugate induced a similar or better antibody response, receptor binding inhibition, and virus neutralization activity against different variants of SARS-CoV-2, compared to mRNA. IgG subclass profiles induced by conjugate and mRNA vaccines were initially dominated by IgG1 and IgG3 then switched to IgG2 and IgG4 dominant profiles during the subsequent six-month period. Polyclonal immune sera from the conjugate and mRNA had similar antibody avidity at multiple time points. Conclusions: In summary, antibody responses in rhesus macaques induced by the RBD-EcoCRM conjugate and the Spike mRNA vaccine are very similar. These results demonstrate the potential for the RBD-EcoCRM conjugate as a vaccine against SARS-CoV-2.Keywords
Funding Information
- Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health
This publication has 83 references indexed in Scilit:
- Comparative analysis of the structural dynamics of diphtheria toxin and CRM197 carrier proteins used in the development of conjugate vaccinesInternational Journal of Pharmaceutics, 2025
- Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19JAMA Internal Medicine, 2024
- The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccinesInternational Journal of Infectious Diseases, 2023
- Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trialeClinicalMedicine, 2023
- mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and EvaluationCurrent Allergy and Asthma Reports, 2023
- Myocarditis following COVID ‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial DiseasesEuropean Journal of Heart Failure, 2022
- Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patientsBiosensors and Bioelectronics, 2022
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta VariantsJAMA, 2022
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesCell, 2022
- US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021JAMA, 2021